Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V C Jordan

Showing results (171-180 of 365) with videos related to

Pageof 37
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 11, 2000
Selective oestrogen receptor modulation: molecular pharmacology for the millenniumA S Levenson, V C Jordan
British Journal of Pharmacology|May 1, 1979
Control of experimental breast cancer by antioestrogenic therapies [proceedings]C J Dix, V C Jordan
British Journal of Pharmacology|February 1, 1979
The binding of [3H]-oestradiol-17 beta in the immature rat uterus during the sequential administration of non-steroidal anti-oestrogensV C Jordan, K E Naylor
Cancer Research|May 15, 1998
The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptorA S Levenson, V C Jordan
British Journal of Pharmacology|January 1, 1980
Antioestrogenic derivatives of nafoxidine stimulate progesterone receptor synthesis in vivo [proceedings]K E Allen, V C Jordan
British Journal of Pharmacology|January 1, 1980
Modulation of nuclear oestrogen receptor levels by oestrogen and antioestrogen [proceedings]C J Dix, V C Jordan
The Journal of Steroid Biochemistry and Molecular Biology|December 1, 1994
Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell linesA S Levenson, V C Jordan
The Journal of Endocrinology|February 1, 1976
Tamoxifen as an anti-tumour agent: effect on oestrogen bindingV C Jordan, L J Dowse
Drug Safety|May 1, 1993
A risk-benefit assessment of tamoxifen therapyW H Catherino, V C Jordan
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|June 1, 1995
Gynecologic effects of tamoxifen and the association with endometrial carcinomaV J Assikis, V C Jordan
Pageof 37

Showing results (171-180 of 365) with videos related to

Sort By:
Pageof 37
European Journal of Cancer (Oxford, England : 1990)|March 11, 2000
Selective oestrogen receptor modulation: molecular pharmacology for the millenniumA S Levenson, V C Jordan
British Journal of Pharmacology|May 1, 1979
Control of experimental breast cancer by antioestrogenic therapies [proceedings]C J Dix, V C Jordan
British Journal of Pharmacology|February 1, 1979
The binding of [3H]-oestradiol-17 beta in the immature rat uterus during the sequential administration of non-steroidal anti-oestrogensV C Jordan, K E Naylor
Cancer Research|May 15, 1998
The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptorA S Levenson, V C Jordan
British Journal of Pharmacology|January 1, 1980
Antioestrogenic derivatives of nafoxidine stimulate progesterone receptor synthesis in vivo [proceedings]K E Allen, V C Jordan
British Journal of Pharmacology|January 1, 1980
Modulation of nuclear oestrogen receptor levels by oestrogen and antioestrogen [proceedings]C J Dix, V C Jordan
The Journal of Steroid Biochemistry and Molecular Biology|December 1, 1994
Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell linesA S Levenson, V C Jordan
The Journal of Endocrinology|February 1, 1976
Tamoxifen as an anti-tumour agent: effect on oestrogen bindingV C Jordan, L J Dowse
Drug Safety|May 1, 1993
A risk-benefit assessment of tamoxifen therapyW H Catherino, V C Jordan
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|June 1, 1995
Gynecologic effects of tamoxifen and the association with endometrial carcinomaV J Assikis, V C Jordan
Pageof 37